United States v. Fallon , 317 F. App'x 128 ( 2008 )


Menu:
  •                                                                                                                            Opinions of the United
    2008 Decisions                                                                                                             States Court of Appeals
    for the Third Circuit
    10-15-2008
    USA v. Fallon
    Precedential or Non-Precedential: Non-Precedential
    Docket No. 07-2350
    Follow this and additional works at: http://digitalcommons.law.villanova.edu/thirdcircuit_2008
    Recommended Citation
    "USA v. Fallon" (2008). 2008 Decisions. Paper 365.
    http://digitalcommons.law.villanova.edu/thirdcircuit_2008/365
    This decision is brought to you for free and open access by the Opinions of the United States Court of Appeals for the Third Circuit at Villanova
    University School of Law Digital Repository. It has been accepted for inclusion in 2008 Decisions by an authorized administrator of Villanova
    University School of Law Digital Repository. For more information, please contact Benjamin.Carlson@law.villanova.edu.
    NOT PRECEDENTIAL
    UNITED STATES COURT OF APPEALS
    FOR THE THIRD CIRCUIT
    No. 07-2350
    UNITED STATES OF AMERICA
    v.
    JAMES C. FALLON,
    Appellant
    On Appeal from the United States District Court
    for the Eastern District of Pennsylvania
    D.C. Criminal No. 02-cr-00324
    (Honorable James T. Giles)
    Argued September 9, 2008
    Before: SCIRICA, Chief Judge, McKEE and SMITH, Circuit Judges.
    Filed: October 15, 2008
    ROBERT EPSTEIN, ESQUIRE (ARGUED)
    Defender Association of Philadelphia
    Federal Court Division
    The Curtis Center, Suite 540 West
    601 Walnut Street
    Philadelphia, Pennsylvania 19106
    Attorney for Appellant
    BERNADETTE A. McKEON, ESQUIRE (ARGUED)
    CHRISTINE E. SYKES, ESQUIRE
    ROBERT A. ZAUZMER, ESQUIRE
    Office of United States Attorney
    615 Chestnut Street, Suite 1250
    Philadelphia, Pennsylvania 19106
    Attorney for Appellee
    OPINION OF THE COURT
    SCIRICA, Chief Judge.
    Appellant James C. Fallon was convicted by a jury of one count of wire fraud and
    three counts of mail fraud. In addition to a prison sentence of twelve months and a day
    (followed by thirty-six months of probation), Fallon was ordered to pay restitution in the
    amount of $55,235.86. On appeal, we affirmed Fallon’s conviction and sentence, but
    vacated the District Court’s restitution order. United States v. Fallon, 
    470 F.3d 542
    (3d
    Cir. 2006). On remand, the District Court imposed an amended restitution order in the
    amount of $57,437.80. Fallon now appeals the Court’s restitution calculation. For the
    following reasons, we will affirm.
    I.
    Fallon is the former president of Derma Genesis, the manufacturer and distributor
    of “Derma Peel,” a dermatological device. On November 4, 1997, the Food and Drug
    Administration (“FDA”) notified Fallon he could not legally market Derma Peel without
    first obtaining clearance from the agency. Nevertheless, in January 1998, Fallon began
    promoting Derma Peel without FDA clearance. Soon after, Fallon began negotiations
    with a medical device financier, American Business Leasing, (“ABL”) to purchase the
    devices. To secure an agreement, Fallon fraudulently submitted a forged letter to ABL
    2
    which claimed to provide FDA approval for distribution of Derma Peel. This letter
    formed the evidentiary basis of the government’s successful prosecution of Fallon.
    Relying upon the forged letter, ABL purchased seventy-eight Derma Peel
    machines from Fallon for lease to medical professionals.1 ABL became aware of Fallon’s
    fraud in September 1998, and shortly thereafter ended its relationship with Derma
    Genesis. Fallon was indicted in 2002 and the District Court entered the judgment of
    conviction and sentence on October 16, 2003. Fallon appealed his sentence and we
    vacated the restitution amount and remanded back to the District Court. After the
    amended restitution order was imposed, Fallon again appealed the judgment, disputing
    the method of calculation used by the District Court.
    On appeal, we consider the District Court’s amended restitution order.2
    1
    On February 18, 1998, shortly after Fallon submitted the fabricated letter to ABL, the
    passage of the Food and Drug Modernization Act exempted Derma Peel from the FDA’s
    clearance requirement. Though Fallon could now legally market Derma Peel without
    FDA clearance, the District Court found Fallon’s representation of FDA approval
    remained material to ABL’s decision to purchase the device. Furthermore, the District
    Court found it was material to certain doctors’ decisions to lease the device from ABL.
    2
    “We review a restitution order under a bifurcated standard: plenary review as to
    whether restitution is permitted by law, and abuse of discretion as to the appropriateness
    of the particular award.” United States v. Quillen, 
    335 F.3d 219
    , 221 (3d Cir. 2003).
    (internal quotations omitted). A district court’s factual finding regarding the amount of
    loss is reviewed for clear error. United States v. Vitillo, 
    490 F.3d 314
    , 330 (3d Cir. 2007).
    3
    II.
    The District Court did not err in confining the restitution calculation to the four
    unenforced lease agreements. Fallon contends the District Court should have aggregated
    ABL’s profits and losses from all of the leases to determine the restitution amount. Under
    Fallon’s approach, there would be no restitution award as it is undisputed ABL generated
    a net profit from the leases. However, under the Mandatory Victims Restitution Act
    (“MVRA”), a defendant is required to pay restitution to a victim for losses proximately
    caused by the defendant’s unlawful conduct. 18 U.S.C. § 3663(a)(1)(A). In Fallon, we
    instructed that “where . . . the government demonstrates that a business transaction was
    consummated due to fraud by the defendant, a commonsense but rebuttable inference
    arises that subsequent losses suffered by the victim of the fraud are sufficiently linked to
    the underlying fraud to support an award of 
    restitution.” 470 F.3d at 549
    .
    On remand, as directed, the District Court correctly focused just on those leases
    which the government demonstrated were proximately caused by the defendant’s
    unlawful conduct and for which the defendant did not provide evidence to rebut the
    inference in favor of the prosecution.3 Because Fallon failed to demonstrate there was an
    3
    The defendant provided evidence to rebut the proximate causation inference for the
    other leases in the first sentencing hearing. See 
    Fallon, 470 F.3d at 549
    . (“As noted,
    approximately $34,000 of the District Court’s $55,235.86 restitution judgment can be
    attributed to lease payments missed by two doctors, one dead and one who filed for
    bankruptcy.”) See also United States v. Fallon, No. 02-324-1, 
    2007 U.S. Dist. LEXIS 32986
    , at *4 (E.D. Pa. May 3, 2007). (“Only lease agreements as to the three entities are
    (continued...)
    4
    intervening cause for these losses other than his fraud, the District Court was correct in
    only including the four leases in the restitution award.4
    A.
    The District Court did not abuse its discretion in finding ABL made a reasonable
    business decision not to enforce its financing agreement. Fallon argues ABL could have
    enforced the outstanding lease agreements, mitigating their losses. But the District Court
    credited the testimony of ABL’s attorney that he advised the company it could face
    allegations of fraudulent inducement if it attempted to enforce the lease agreements for
    Derma Peel. Accordingly, ABL decided not to attempt to enforce the outstanding leases
    because ABL’s contractual relationship with its customers included a duty of good faith
    and fair dealing.5 See, e.g., DiCarlo v. St. Mary Hosp., No. 05-1665, 2006 U.S. Dist.
    3
    (...continued)
    now at issue. . . . As to each of the four devices at issue, Defendant has presented no
    evidence or testimony from any of the contracting parties that the devices were returned
    for reasons other than the misrepresentation regarding FDA approval.”)
    4
    The District Court’s restitution calculation is as follows: the government presented
    unrefuted evidence that ABL was unable to collect $24,743.64 from the Cosmetic Laser
    Center, $42,646.10 on two leases from Dr. Griffin, and $48.06 from the Plastic Surgery
    Center. The total losses were found to be $67,437.80. The court then offset the restitution
    amount by $2,500, the residual value of each of the four machines after the leases were
    terminated and the machine was returned to ABL, as stipulated in the contract. The total
    restitution amount is therefore $57,437.80.
    5
    Fallon claims he should not be responsible for the resulting losses because it was
    possible for ABL to enforce the outstanding lease agreements against the doctors.
    Fallon’s argument is three-fold: (1) ABL’s lease agreements contained a so-called “hell or
    (continued...)
    
    5 LEXIS 49000
    , at *20, (D.N.J. July 19, 2006), adopted by DiCarlo v. St. Mary Hosp., 
    530 F.3d 255
    , 260 (3d Cir. 2008) (“A plaintiff may be entitled to relief under the covenant [of
    good faith and fair dealing] if its reasonable expectations are destroyed when a defendant
    acts with ill motives and without any legitimate purpose.” (citation omitted)). Having
    discovered its customers may have been fraudulently induced to purchase Derma Peel
    machines, ABL acted in accord with its duties in declining to enforce the outstanding
    leases.6
    B.
    The District Court did not err by deducting only the default residual value of
    Derma Peel machines from the restitution award. Fallon argues the Court should have
    5
    (...continued)
    high water” provision, which protected ABL from liability (the lease stated ABL did not
    ensure the quality of the products it financed), (2) ABL did not engage in fraudulent
    conduct because the device was exempted from the FDA’s clearance requirement before
    it was purchased by ABL, and (3) ABL did not make its fraudulent representations
    knowingly. We find these arguments to be without merit. To compel a company to pursue
    litigation to enforce an agreement which it suspects was fraudulently entered into is
    unreasonable and not a recognizable legal duty.
    6
    Initially we stated, “Whether the doctors may have had colorable fraudulent
    inducement claims is far from certain.” 
    Fallon, 470 F.3d at 550
    . Nevertheless, given the
    presumption that Fallon was the proximate cause of ABL’s losses, Fallon still has the
    burden of proving ABL was unreasonable in failing to enforce the outstanding leases.
    Fallon did not meet this burden. ABL presented unrefuted evidence at least one doctor
    threatened to take legal action against ABL for fraudulently inducing the lease agreement
    if ABL attempted to enforce the Derma Peel lease agreement. Fallon wishes this Court to
    require ABL to litigate each claim, a costly, impractical, and unpredictable demand. Even
    if, as Fallon predicts, ABL’s lease agreements were legally enforceable, it would be
    improper and overreaching to require a fraud victim to pursue every possible avenue to
    mitigate the costs of the crime perpetrated upon them.
    6
    deducted the residual value of the devices at the time ABL stopped enforcing the lease
    agreements. Under the MVRA, the value of property at the time it is returned to the
    victim must be deducted from the restitution award. 18 U.S.C. § 3663(b)(I)(B)(ii).
    Fallon argues ABL should have sought to have the machines returned immediately so
    they could be resold or leased. Fallon claims machines returned before their lease
    agreements were set to expire had a higher residual value than $2,500 because they had
    been used fewer times than expected, and this extra value should be deducted from the
    restitution amount. The District Court disagreed and credited Fallon for the default
    minimal residual value of the four machines as stipulated in the contract ($2,500 each).
    As noted, Fallon has the burden of refuting the presumption that ABL’s losses
    were due to his fraud. 
    Fallon, 470 F.3d at 549
    . To satisfy this burden, he would have to
    establish that if the Derma Peel machines were returned to ABL, they could have been
    resold or released at a value higher than $2,500. In other words, he would need to show
    ABL could have mitigated its losses, but did not.
    Fallon did not meet this burden. The District Court credited the testimony of a
    prosecution witness, FDA Special Agent Douglas Loveland, who stated the devices
    would have been returned to the device distributors who worked for Fallon, rather than to
    ABL. Fallon presented no evidence indicating the machines were returned to ABL rather
    than the distributor, or even that ABL would have been able to resell or release the
    machines for more than $2,500 to recover some of its lost profits. The District Court
    7
    credited Fallon $2,500 for the minimal residual value of each machine as stipulated in the
    contract. This placed ABL in the position it would have been in had the contracts been
    fully performed. As such, we see no error in the District Court’s findings.
    Accordingly, we will affirm the restitution award as determined by the District
    Court.
    8
    

Document Info

Docket Number: 07-2350

Citation Numbers: 317 F. App'x 128

Filed Date: 10/15/2008

Precedential Status: Non-Precedential

Modified Date: 1/12/2023